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Purpose of the study
The 48-week efficacy and safety analysis of the next-gener-
ation NNRTI etravirine (ETR) in the DUET studies has
recently been completed. We report safety results from a
planned pooled analysis, according to baseline hepatitis
co-infection status.
Methods
HIV-1-infected patients on stable but virologically failing
therapy were randomised to receive either ETR 200 mg
twice daily or placebo, both in combination with a back-
ground regimen (BR) consisting of darunavir with low-
dose ritonavir (DRV/r), investigator-selected NRTIs and
optional enfuvirtide (ENF). Hepatitis B and/or C virus
(HBV and/or HCV) co-infection status was confirmed by
hepatitis B surface antigen or HCV antibody and qualita-
tive HCV ribonucleic acid (RNA). Co-infected patients
were eligible if they were clinically stable, with aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) levels <5 × the upper limit of normal and did not
require anti-hepatitis treatment. Adverse events (AEs) and
laboratory parameters were analysed.
Summary of results
At baseline, HBV and/or HCV status was known for 1,129
HIV-1-infected patients. Of these, 139 patients (12.3%)
were co-infected with HBV and/or HCV; the sample size
was too small to compare HBV and HCV groups sepa-
rately. Median treatment duration for this analysis was
52.3 vs. 51.0 weeks in the ETR + BR and placebo + BR
groups, respectively. In co-infected patients, grade 3 or 4
AEs, serious AEs and deaths were less frequent with ETR
than with placebo. Grade 3 or 4 AST/ALT elevations were
more frequent in co-infected patients receiving ETR, how-
ever, the differences between the ETR and placebo groups
was small. The incidence of grade 3 or 4 hepatic AEs was
similar in both treatment groups. See table in Figure 1.
Conclusion
In general, the incidence and severity of AEs with ETR was
similar to placebo, irrespective of co-infection status. The
incidence of hepatic AEs and grade 3 or 4 AST/ALT eleva-
tions was higher in co-infected patients than in non-co-
infected patients in both treatment groups, consistent
with the underlying chronic hepatitis condition. ETR did
not increase hepatic toxicity in patients with hepatitis co-
infection and was generally well tolerated in all patients.
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